Chronic periodontitis in mild to moderate forms is considered the most common form of periodontitis occurring worldwide with prevalences from 13 to 57% in different populations depending upon oral hygiene and socioeconomic status ([@CIT0001]). Treatment combinations are often recommended for periodontitis. Such combinations include removal of tooth-borne bacterial plaque and calculus often in conjunction with periodontal surgery (SURG). Addition of antibiotics aims at suppressing pathogenic microorganisms and allowing recolonization with those compatible with health ([@CIT0002]).

In the current study, the effectiveness of eight different therapies including combinations of therapies on two established markers of periodontitis, pocket depth (PD) and clinical attachment level (CAL), was compared. The therapies were scaling and root planing (SRP), SURG, and systemic and local antibiotics.

The necessity for pocket elimination by SURG has been challenged. The main objective of SURG is to contribute to long-term preservation of the periodontium by promoting plaque removal and infection control. However, it has been suspected that SURG may initiate loss of CAL through a detrimental effect on osteoblasts. Subantimicrobial doses of doxycycline reduce gingival collagenolytic activity by inhibiting neutrophil matrix metalloproteinases ([@CIT0003]--[@CIT0008]). The present study assessed whether loss of CAL associated with SURG could be diminished by combining SURG with antibiotics such as systemic amoxicillin (AMOX) and systemic metronidazole (MET) and locally delivered tetracycline (TET).

Studies on periodontal treatment have generally indicated that it immediately improves clinical parameters of periodontitis. Usually, adjunctive systemic antibiotic treatment provides better results than SRP alone, particularly in terms of PD reduction and gain of CAL ([@CIT0009]--[@CIT0011]).

Several studies have tested the effect of local application of TET in the management of periodontitis ([@CIT0012]--[@CIT0016]). MET has been used alone ([@CIT0011], [@CIT0017], [@CIT0018]) or in combination with AMOX ([@CIT0018]--[@CIT0020]). AMOX has been used to suppress periodontal pathogens and increase the gain of clinical attachment ([@CIT0021]). MET+AMOX have been applied successfully in the treatment of adult periodontitis, especially in *Aggregatibacter actinomycetemcomitans*-associated infections ([@CIT0022], [@CIT0023]). Even though systemically administered adjunctive antibiotics may provide better clinical results than SRP alone, little is known if any of these agents are more effective than others when long-term clinical effects are considered.

The effectiveness of a therapy is usually masked by risk factors for health such as smoking habits. Responses after periodontal treatment are thought to be modified by cigarette consumption. Current smokers experience poorer clinical responses than former or never smokers ([@CIT0024]--[@CIT0026]). A therapy may also work well in one ethnic group and fail to reproduce similar results in a different ethnic group. Differences have been demonstrated in the prevalence of periodontitis between and across continents ([@CIT0027], [@CIT0028]). In the present study, white Americans, Swedes, African Americans, and Asians were examined to see how they maintained over time the beneficial clinical status achieved by different periodontal therapies. There are no clear inherent differences between males and females in their susceptibility to periodontitis, but men have worse periodontal health than women in multiple studies from different populations ([@CIT0028]--[@CIT0030]).

When analyzing clustered longitudinal clinical data on periodontal disease, tooth sites are nested in teeth, which are in turn nested within patients and share a common feature of correlated observations. Because of this hierarchical structure ([Fig. 1](#F0001){ref-type="fig"}), analysis assuming independence of observations is rendered inappropriate. Any method of analysis that attempts to aggregate the data at patient level results in loss of valuable information and may not explicitly reflect the site-specific nature of periodontal disease ([@CIT0031], [@CIT0032]). Furthermore, it is reasonable to assume that based on the severity of the disease, periodontal therapies are likely to vary not only between patients but also between tooth sites in subjects.

![Structure of the clustered longitudinal data for patient 1.](JOM-4-17535-g001){#F0001}

The use of random effects in multilevel modeling is one common and convenient way to model such grouping structure ([@CIT0033], [@CIT0034]). It is therefore appropriate to consider 'site within tooth' and 'tooth within patient' to be random factors. We used this approach that takes into account the clustering effect of the data and provides reasonable explanations for how therapeutic effects change over time.

The main aim of the present study was to compare the clinical effectiveness of eight different therapies in periodontitis. We examined changes in PD and CAL to assess treatment effects. In particular, we were interested in comparing if patients receiving SURG alone maintained their improved clinical status for a shorter period than patients treated with SURG combined with systemic or local antibiotics. The hypothesis was that SURG combined with systemic or local antibiotics gives better long-term clinical results than SURG alone. All treatments were compared to SRP (control).

The study also aimed at determining whether treatment reduced PD in sites or subjects by\>1.5 mm or if it could produce CAL gain of \>1.5 mm. We also examined the effects on the periodontal treatment of underlying explanatory variables such as age, smoking habits, race, nationality and gender. The current study, based on previously published data ([@CIT0035]), is an attempt to mathematically model infectious disease using periodontitis as a basis.

Materials and methods {#S0001}
=====================

Patient population, inclusion and exclusion criteria, periodontal treatment, and clinical monitoring have been described in detail previously ([@CIT0035]). Only a brief version is given here.

Study group {#S20002}
-----------

A total of 229 (109 females and 120 males) American (*n=*134) and Swedish (*n=*95) patients aged 20--79 years (mean 48) were originally recruited for this 2-year follow-up study. The Americans were collected at the Forsyth Institute and at Boston University, Boston, and the Swedes at the University of Göteborg. In the Swedish population, 98% of the subjects were white versus 60% in the US population. Current smokers constituted 57% of Swedish subjects and 25% in US subjects. Patients were in good general health and had at least 15 natural teeth including minimum one molar in each quadrant and at least 4 teeth with PD≥5 mm and 8 teeth with CAL\>3 mm at baseline. Males and females of any race were accepted to participate. Participants, of whom 187 completed the study, were followed up for 2 years and the data on different clinical measurements recorded from all teeth except third molars. The experiments were undertaken with the understanding and written consent of each subject. The study design was independently reviewed and approved by the Review Boards of the Forsyth Institute, Boston University, and the Ethics Committee at the University of Göteborg.

*Exclusion criteria* were known allergies to the antibiotics to be used, antibiotic or periodontal treatment last 3 months, pregnancy, nursing, or systemic conditions that would influence the course of periodontal treatment, or allergy to amoxicillin, metronidazole, tetracycline, lidocaine, or chlorhexidine.

Experimental design and treatment {#S20003}
---------------------------------

The patients were stratified into current smokers and non-smokers and randomly assigned to permuted blocks of eight different treatment combinations. A clinical co-coordinator assigned the patients to each group. [Table 1](#T0001){ref-type="table"} summarizes the baseline characteristics of the patients in the eight groups. All patients had equal chances of being assigned to any of the therapies. The treatments were ([@CIT0001]) SRP alone; ([@CIT0002]) SRP+SURG+AMOX+MET; ([@CIT0003]) SRP+SURG+TET; ([@CIT0004]) SRP+SURG; ([@CIT0005]) SRP+AMOX+MET+TET; ([@CIT0006]) SRP+AMOX+MET; ([@CIT0007]) SRP+TET; and ([@CIT0008]) SRP+SURG+AMOX+MET+TET ([Table 1](#T0001){ref-type="table"}). Subjects were monitored at baseline and at 3, 6, 12, 18, and 24 months.

###### 

Baseline characteristics of the study subjects

                                                                        Treatments                                                                         
  --------------------------------------------------------------------- ------------ --------- --------- --------- --------- --------- --------- --------- -------
  n                                                                     23           18        22        21        28        26        26        23        0.440
  Age (years)                                                           46±12        50±11     50±10     48±8      48±7      46±10     45±10     50±11     0.903
  Americans (*n*)                                                       13           6         10        11        16        15        15        11        0.755
  Males                                                                 12           10        12        12        13        17        11        11        0.812
  Smoking status -- number (%)                                                                                                                             
   Never smoked                                                         9 (39)       6 (33)    3 (14)    6 (29)    5 (18)    3 (12)    9 (34)    5 (22)    0.135
   Former smoker                                                        7 (30)       4 (22)    9 (41)    7 (33)    8 (29)    14 (54)   10 (38)   7 (30)    0.135
   Current smoker                                                       7 (30)       8 (44)    10 (45)   8 (38)    15 (53)   9 (34)    7 (27)    11 (48)   0.533
  Race or ethnic group -- number (%)[†](#TF0001){ref-type="table-fn"}                                                                                      
   White                                                                17 (74)      14 (78)   21 (95)   18 (86)   22 (79)   21 (81)   19 (73)   18 (78)   0.641
   Black                                                                4 (17)       2 (11)    1 (5)     2 (10)    5 (18)    4 (15)    6 (23)    2 (9)     0.474
   Asian                                                                2 (9)        --        --        --        1 (3)     --        --        1 (4)     0.325
   Other                                                                --           2 (11)    --        1 (4)     --        1 (4)     1 (4)     2 (9)     0.266
  Percentage of sites with                                                                                                                                 
   Plaque                                                               51.1         48.6      50.0      52.6      53.8      48.0      52.0      52.2      
   Gingival redness                                                     53.5         54.5      48.8      50.0      56.0      52.2      57.8      53.7      
   Bleeding on probing                                                  54.8         52.9      52.4      56.8      52.8      51.0      53.1      53.5      
   Suppuration                                                          32.4         10.0      21.4      36.4      34.9      29.7      35.0      20.7      
   Mean pocket depth (mm)                                               7.0±2.0      6.8±1.5   6.7±1.5   7.0±1.7   7.1±1.9   6.9±1.7   7.1±1.7   6.9±1.7   0.565
   Mean clinical attachment level (mm)                                  6.7±2.8      5.8±2.1   6.4±2.2   6.4±2.2   7.2±2.5   7.1±2.5   6.7±2.3   6.8±2.5   0.890
   Number of missing teeth                                              2.6±2.8      4.4±3.7   4.1±2.7   3.6±2.9   3.7±3.2   2.8±3.3   3.8±3.4   5.0±3.5   0.183

The eight treatments were: 1. Scaling and root planing (SRP), 2. SRP+surgery, systemic amoxicillin+metronidazole, 3. SRP+surgery, locally delivered tetracycline, 4. SRP+surgery, 5. SRP+systemic amoxicillin+metronidazole and local tetracycline, 6. SRP+systemic amoxicillin+metronidazole, 7. SRP+locally delivered tetracycline, and 8. SRP+surgery+amoxicillin+metronidazole+locally delivered tetracycline.

There were no significant baseline differences between patients who were in the control group (SRP) and those receiving other treatments as evidenced by the large *p*-values.

Plus-minus values are means±standard deviations.

†Race was self-reported. Other races included Native Hawaiians, American Indian/Alaskan and unknown.

### SRP

At baseline, all subjects received SRP performed under local anesthesia and usually finished in four weekly visits. During SRP treatment, subjects rinsed twice daily with 0.1% chlorhexidine.

### Systemic antibiotics

Systemic antibiotics were given as 14 days of medication (metronidazole 250 mg×3 and amoxicillin 500 mg×2). This therapy started immediately after the first session of SRP and was administered parallel to local tetracycline fiber application. Compliance was reported by the patients.

### Local tetracycline

Local antibiotics were given as tetracycline fibers (Actisite®, Proctor and Gamble, Cincinnati, OH) in pockets≥5 mm immediately after mechanical instrumentation at the SRP visits. The fibers were removed after 7 days, i.e. at the next appointment for quadrant-wise SRP.

### Surgery

Surgery was performed at the 3-month monitoring visit following SRP. Subjects who had residual PDs≥5 mm and bleeding on probing (BOP) received modified Widman flap surgery at weekly intervals as needed. Chlorhexidine, 0.1%, was used as a mouth rinse for 1 min twice daily during the surgical phase and 2 weeks following the last surgical session.

### Home care

Each subject was provided with a powered toothbrush and triclosan-containing toothpaste and instructed to brush twice daily and to perform daily interdental cleaning with dental floss, toothpicks, and/or interdental brushes.

### Post-treatment care

At each follow-up visit, the patients' oral hygiene standard was checked and reinforced when indicated. Furthermore, at the 12-month recall, all sites with PD≥5 mm and BOP were subjected to subgingival mechanical debridement.

Clinical assessments {#S20010}
--------------------

At each visit, visible plaque, gingivitis, BOP, suppuration, probing depth, and CAL were recorded at four sites per tooth (mesiobuccal, distobuccal, distolingual, and mesiolingual). Full-mouth computations included only approximal sites measuring≥5 mm at baseline. At each study visit, PD and CAL measurements were repeated and the means of the pairs of each measurement were used to determine changes in these parameters. A North Carolina periodontal probe (Hu-Friedy, Chicago, IL, USA) was used for PD and CAL recordings. The same clinician did measurements at all visits for a given subject, but the clinician making the measurements did not perform treatment on that subject. Each clinician examined or treated the same number of patients in each group. The calibration of the performance of clinicians was done as described by Haffajee et al. ([@CIT0010]). Correlation within examiner was 0.82 for PD and 0.78 for CAL and between examiners pairwise correlations were 0.75 for PD and 0.82 for CAL. Correlations between centers was controlled by calibration sessions.

Data structure {#S20011}
--------------

Clinical parameters were measured at baseline and at 3, 6, 12, 18, and 24 months for each tooth site with PD≥5 mm. The patients were at the highest level of the structural data hierarchy (level 4), the 28 teeth excluding the third molars in each patient were in level 3, and level 2 comprised the four tooth sites. The bottom level of the data hierarchy had the time variables at baseline and the five monitoring time points. All the variables indicating the units of analysis (level 2) and the clusters of units (levels 3 and 4) were assumed to be random factors in the analysis.

Multilevel modeling {#S20012}
-------------------

We considered a four-level model with random intercept and random effect of time on patients at level 3, random intercept for teeth at level 2, and tooth sites at level 1. The PD for any given patient at time *t* corresponding to the baseline visit and the 3, 6, 12, 18, and 24 months visits on site *i*, in tooth *j* nested within patient *k* denoted PD~tijk~, is given by model 1:$$\text{PD}_{\text{tijk}} = \left\{ \begin{array}{l}
{\beta_{\text{0}} + \beta_{\text{1}}\text{time}_{\text{t}} + \beta_{\text{2}}\text{treatment}_{\text{ijk}} + \beta_{\text{2}}\text{gender}_{\text{ijk}}} \\
{+ \beta_{\text{4}}\text{age}_{\text{ijk}} + \beta_{\text{5}}\text{race}_{\text{ijk}} + \beta_{\text{6}}\text{nationality}_{\text{ijk}}} \\
{+ \beta_{\text{7}}\text{smoking}_{\text{ijk}} + \beta_{\text{8}}\text{baseline\ PD}_{\text{ijk}}} \\
{+ \beta_{\text{9}}\text{plaque}_{\text{ijk}} + \beta_{\text{10}}\text{BOP}_{\text{ijk}} + \beta_{\text{11}}\text{suppuration}_{\text{ijk}}} \\
{+ \beta_{\text{12}}\text{redness}_{\text{ijk}}{+ \beta_{\text{13}}}\text{time}_{\text{t}}\text{treatment}_{\text{ijk}}(\text{fixed})} \\
{+ \alpha_{\text{0k}} + \alpha_{\text{0k}}\text{time}_{\text{t}} + \alpha_{\text{0jk}} + \alpha_{\text{0ijk}} + \varepsilon_{\text{tijk}}(\text{random})} \\
\end{array} \right.$$

The parameter estimates β~0~ through to β~13~ represent fixed effects associated with the intercept, time effect, treatment, gender, age, race, nationality, smoking habits, baseline PD, plaque accumulation, BOP, suppuration, gingival redness, and the interaction of treatment with time. For the random part, α~0k~ and α~1k~ represent the patient random effect associated with the intercept and time slope, respectively. α~0jk~ is the random effect of a tooth nested within a patient, α~0ijk~ the random effect of a site nested in a tooth, which in turn is nested in patients, and ɛ~tijk~ is the random error, which is assumed to be homogeneous and uncorrelated with mean 0 and variance σ^2^.

The model parameter estimates were obtained in the statistical software R using the restricted maximum likelihood method (REML). We also considered a similarly structured model for CAL loss.

A therapy that reduces PD by\>1.5 mm or results in gain of CAL of \>1.5 mm would be considered clinically effective. Such binary response variables were also of interest. The binary responses were modeled by logistic multilevel regression given by model 2:

*Y* ~tijk~∼Binomial(1, *p* ~tijk~)$$\text{logit}(p_{\text{tijk}}) = \left\{ \begin{array}{l}
{\beta_{\text{0}} + \beta_{\text{1}}\text{time}_{\text{t}} + \beta_{\text{2}}\text{treatment}_{\text{ijk}}} \\
{+ \beta_{\text{3}} + \text{gender}_{\text{ijk}} + \beta_{\text{4}}\text{age}_{\text{ijk}} + \beta_{\text{5}}\text{race}_{\text{ijk}}} \\
{+ \beta_{\text{6}}\text{nationality}_{\text{ijk}}{+ \beta_{\text{7}}\text{smoking}_{\text{ijk}}}} \\
{+ \beta_{\text{8}}\text{baseline\ PD}_{\text{ijk}}{+ \beta_{\text{9}}\text{plaque}_{\text{ijk}}}} \\
{+ \beta_{\text{10}}\text{BOP}_{\text{ijk}} + \beta_{\text{11}}\text{suppuration}_{\text{ijk}}} \\
{+ \beta_{\text{12}}\text{redness}_{\text{ijk}}} \\
{{+ \beta_{\text{13}}}\text{time}_{\text{t}}\text{treatment}_{\text{ijk}}(\text{fixed}){+ \alpha_{\text{0k}}}} \\
{+ \alpha_{\text{1k}}\text{time}_{\text{t}} + \alpha_{\text{0jk}} + \alpha_{\text{0ijk}} + \varepsilon_{\text{tijk}}(\text{random})} \\
\end{array} \right.$$

*Y* ~tijk~ is 1 if patient *k* at time *t* on site *i* nested in tooth *j* had a decrease in PD of \>1.5 mm and 0 otherwise. The parameter estimates are defined as in model 1. The random effects α~0k~, α~1k~, α~0jk~, and α~0ijk~ are assumed to be normally distributed with mean 0 and variances $\text{σ}_{0\text{k}}^{2}$, $\text{σ}_{1\text{k}}^{2}$, $\text{σ}_{0\text{jk}}^{2}$, and $\text{σ}_{0\textit{ijk}}^{2}$, respectively. ɛ~tijk~ has mean 0 and variance σ^2^. However, interest was on fixed effects, particularly changes in treatment effect over time. Random effects only aided in describing variation in the population under study. We considered a similarly structured model for CAL gain of\>1.5 mm. These generalized linear mixed models were estimated by Laplace approximations through the *lmer* routine in R.

Results {#S0013}
=======

Dropout rate of the US subjects (32% at the Forsyth Institute, 24% at Boston University) was much greater than in the Swedish material (7%). Those in the SURG group dropped out more often than those receiving antibiotics. During the active treatment phase, 25 teeth were extracted, 41 during post-therapy monitoring. SURG increased the number of extracted teeth whereas systemic antibiotics gave reduced tooth loss. During follow-up, 66 teeth were extracted in 48 subjects.

There were no significant baseline differences between patients in the control group (SRP) and those receiving other treatments ([Table 1](#T0001){ref-type="table"}).

Pocket depth {#S20014}
------------

[Table 2](#T0002){ref-type="table"} gives mean changes in PD for the effect of all treatments over time when compared to SRP obtained by fitting model 1. As expected, SURG was more effective in PD reduction after 6 months but combining it with systemic AMOX and MET gave better long-term clinical improvement. Positive estimates represent mean PD increase whereas negative estimates mean PD decrease at various time points. For example, the estimated effect of AMOX+MET+TET produced significant negative estimates after 6 months, suggesting that patients treated with AMOX+MET+TET had significant PD reductions over time compared to SRP. However, SURG+AMOX+MET+TET had larger significant estimates in absolute terms after 6 months, suggesting that there were more PD decrease for patients on this combination therapy than for any other therapy across the study period when compared to SRP.

###### 

Results from fitting a linear multilevel regression model for changes in treatment effect on PD over time on sites that had a baseline PD of at least 5 mm using the restricted maximum likelihood estimation (REML)

  Therapy             3 months estimate 95% (CI)                            6 months estimate 95% (CI)                               12 months estimate 95% (CI)                              18 months estimate 95% (CI)                              24 months estimate 95% (CI)
  ------------------- ----------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------
  SURG+AMOX+MET       0.37 (0.21, 0.53)[\*](#TF0002){ref-type="table-fn"}   −0.34 (−0.50, −0.19)[\*](#TF0002){ref-type="table-fn"}   −0.32 (−0.47, −0.16)[\*](#TF0002){ref-type="table-fn"}   −0.32 (−0.47, −0.16)[\*](#TF0002){ref-type="table-fn"}   −0.36 (−0.53, −0.21)[\*](#TF0002){ref-type="table-fn"}
  SURG+TET            0.53 (0.38, 0.68)[\*](#TF0002){ref-type="table-fn"}   −0.44 (−0.59, −0.30)[\*](#TF0002){ref-type="table-fn"}   −0.22 (−0.37, −0.07)[\*](#TF0002){ref-type="table-fn"}   −0.28 (−0.42, −0.13)[\*](#TF0002){ref-type="table-fn"}   −0.38 (−0.52, −0.23)[\*](#TF0002){ref-type="table-fn"}
  SURG                0.25 (0.11, 0.40)[\*](#TF0002){ref-type="table-fn"}   −0.46 (−0.60, −0.32)[\*](#TF0002){ref-type="table-fn"}   −0.15 (−0.29, −0.01)[\*](#TF0002){ref-type="table-fn"}   −0.20 (−0.34, −0.06)[\*](#TF0002){ref-type="table-fn"}   −0.20 (−0.34, −0.06)^[\*](#TF0002){ref-type="table-fn"}^
  AMOX+MET+TET        0.12 (−0.02, 0.25)                                    −0.26 (−0.40, −0.13)[\*](#TF0002){ref-type="table-fn"}   −0.17 (−0.30, −0.03)[\*](#TF0002){ref-type="table-fn"}   −0.20 (−0.34, −0.07)[\*](#TF0002){ref-type="table-fn"}   −0.29 (−0.41, −0.15)[\*](#TF0002){ref-type="table-fn"}
  AMOX+MET            0.17 (0.02, 0.33)[\*](#TF0002){ref-type="table-fn"}   −0.02 (−0.18, 0.13)                                      −0.03 (−0.19, 0.12)                                      −0.03 (−0.19, 0.12)                                      −0.12 (−0.27, 0.05)
  TET                 −0.07 (0.20, 0.07)                                    −0.03 (−0.17, 0.10)                                      0.10 (−0.03, 0.24)                                       −0.11 (−0.24, 0.03)                                      0.04 (−0.17, 0.10)
  SURG+MET+AMOX+TET   −0.10 (−0.24, 0.05)                                   −0.73 (−0.88, −0.59)[\*](#TF0002){ref-type="table-fn"}   −0.57 (−0.72, −0.42)[\*](#TF0002){ref-type="table-fn"}   −0.55 (−0.70, −0.41)[\*](#TF0002){ref-type="table-fn"}   −0.60 (−0.74, −0.44)[\*](#TF0002){ref-type="table-fn"}

After 6 months, all therapies except AMOX+MET and TET produced good clinical benefits, which were maintained during the whole study period compared with SRP. 6 months after treatment, patients who were on AMOX+MET+TET had a mean PD reduction of 0.26 mm more than those who were on SRP only. After 12 months, the same patients had a mean reduction in PD of 0.17 mm, 6 months later it was 0.20 mm and at 24 months the mean reduction in PD was 0.29 mm compared to patients on SRP only. However, reductions in mean PD were not consistent over time. Most reductions in PD were observed at 6 months and 24 months with reasonable gains in-between. Sites that were treated with SURG+MET+AMOX+TET experienced more PD reductions over time than any other treatment when compared to SRP. Sites that were only treated with antibiotics had minimal reduction in PD compared to sites that were surgically treated and then treated with antibiotics. If antibiotics alone are to be used, then better clinical results over time are obtained if AMOX+MET+TET are applied.

All therapies were compared to SRP. Other fixed effects of the model are given in [Table 3](#T0003){ref-type="table"}.

\*Significant results at 0.05 when compared to SRP. Positive estimates represent mean PD increase whereas negative estimates indicate mean PD decrease.

Fig. S1 in the Appendix section is a plot of the mean PD at each study time point. It shows that sites treated with SURG+AMOX+MET+TET had the least mean PD while sites that were treated with SRP and TET had the largest mean PD. A plot of the mean difference in PD from the mean PD at the previous visit also shows similar trends with SURG+AMOX+MET+TET producing the least PD (Fig. S3). In Fig. S2, sites that were treated by SRP and with TET reverted to baseline conditions after 6 months.

Fixed effects on PD {#S20015}
-------------------

[Table 3](#T0003){ref-type="table"} shows the fixed effects on PD from fitting model 1. The overall estimated effect of age on PD was significant \[*0.01(0.01, 0.03)*\]. This means that, for every year increase in age, the PD was expected to increase by 0.01 mm. However, the effects of gender and nationality were not significant. The overall effect of site-level covariates (accumulation of plaque, BOP, gingival redness, and suppuration) on PD was highly significant.

###### 

Results from fitting a linear multilevel regression model for treatment effect and other fixed effects on PD and CAL on sites that had a baseline PD of at least 5 mm using the restricted maximum likelihood estimation (REML)

                            PD                                                         CAL
  ------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Intercept                 2.57 (2.20, 2.94)[\*](#TF0003){ref-type="table-fn"}        −0.54 (−1.33, 0.21)
  Time effect                                                                          
   3 months                 −1.58 (−1.68, −1.48)[\*](#TF0003){ref-type="table-fn"}     −0.87 (−1.01, −0.73)[\*](#TF0003){ref-type="table-fn"}
   6 months                 −1.57 (−1.68, −1.48)^[\*](#TF0003){ref-type="table-fn"}^   −0.68 (−0.81, −0.53)[\*](#TF0003){ref-type="table-fn"}
   12 months                −1.71 (−1.81,−1.61)[\*](#TF0003){ref-type="table-fn"}      −0.71 (−0.86, −0.58)[\*](#TF0003){ref-type="table-fn"}
   18 months                −1.69 (−1.79, −1.59)[\*](#TF0003){ref-type="table-fn"}     −0.64 (−0.78, −0.50)[\*](#TF0003){ref-type="table-fn"}
   24 months                −1.58 (−1.67, −1.48)^[\*](#TF0003){ref-type="table-fn"}^   −0.53 (−0.67, −0.38)^[\*](#TF0003){ref-type="table-fn"}^
   Age                      0.01 (0.01, 0.03)[\*](#TF0003){ref-type="table-fn"}        0.03 (0.01, 0.04)[\*](#TF0003){ref-type="table-fn"}
  Smoking habits                                                                       
   Former smokers           0.19 (0.02, 0.35)[\*](#TF0003){ref-type="table-fn"}        −0.15 (−0.51, 0.19)
   Current smokers          0.23 (0.08, 0.38)[\*](#TF0003){ref-type="table-fn"}        0.52 (0.19, 0.86)[\*](#TF0003){ref-type="table-fn"}
  Tooth site effects                                                                   
   Baseline probing depth   0.51 (0.50, 0.52)[\*](#TF0003){ref-type="table-fn"}        0.63 (0.61, 0.64)[\*](#TF0003){ref-type="table-fn"}
   Accumulation of plaque   0.01 (−0.02, 0.04)                                         0.21 (0.18, 0.26)[\*](#TF0003){ref-type="table-fn"}
   Gingival redness         0.16 (0.13, 0.19)[\*](#TF0003){ref-type="table-fn"}        0.10 (0.06, 0.14)[\*](#TF0003){ref-type="table-fn"}
   Bleeding on probing      0.45 (0.42, 0.47)[\*](#TF0003){ref-type="table-fn"}        0.42 (0.38, 0.45)[\*](#TF0003){ref-type="table-fn"}
   Suppuration              0.76 (0.66, 0.86)[\*](#TF0003){ref-type="table-fn"}        0.70 (0.56, 0.85)[\*](#TF0003){ref-type="table-fn"}
  Nationality: Swedish      0.08 (−0.06, 0.22)                                         0.73 (0.43, 1.05)[\*](#TF0003){ref-type="table-fn"}
  Gender: Males             0.03 (−0.10, 0.16)                                         0.41 (0.12, 0.69)[\*](#TF0003){ref-type="table-fn"}

Sites experienced significant reductions in mean PD and CAL over time. For each year increase in age, mean PD increased by 0.01 mm and CAL also increased by 0.03 mm. Tooth site effects such as accumulation of plaque, bleeding on probing, suppuration and gingival redness as well as smoking were all significant predictors of deeper pockets. Former smokers had pockets that were on average 0.19 mm deeper than patients who had never smoked and those who were smoking had pockets that were on average 0.23 mm deeper than patients who had never smoked before. Patients who suppurated had pockets that were 0.76 mm deeper than those who did not while those who bled on probing had pockets that were 0.45 mm deeper than patients who did not bleed on probing.

On average, treated sites were expected to have a CAL gain of 0.87 mm after 3 months and only 0.53 mm after 24 months compared to baseline conditions. Males and Swedish subjects experienced significant losses in CAL. Significant losses in CAL were also observed in subjects who smoked. All tooth site effects which include accumulation of plaque, bleeding on probing, suppuration and gingival redness increased mean CAL.

\*Significant results at 0.05 when compared to SRP at baseline visit.

Smoking habits {#S20016}
--------------

Both past \[*0.19 (0.02, 0.35)*\] and present \[*0.23 (0.08, 0.38)*\] smoking habits increased PD significantly by 0.19 and 0.23 mm, respectively.

We also fitted a model with a third-order interaction between treatment, time, and smoking status in order to investigate to what extent treatment effect varied with smoking status (not shown). A significant third-order interaction was found with regard to both PD and CAL. This means that the effect of treatment on either PD or CAL differed significantly between smokers and non-smokers. The difference was clearly expressed for the reference group (SRP), in favor of the non-smokers, while for the other treatment groups, the difference was somewhat smaller.

Pairwise treatment comparison on PD {#S20017}
-----------------------------------

We carried out a Tukey\'s all-pairwise comparison of the treatments on PD to establish those statistically significant from each other at specific time points. The results are given in Table S1 and include only comparisons that had significant outcome. After 3 months, SURG+TET were the least effective treatment when compared to AMOX+MET, TET, and SURG+AMOX+MET+TET. After 6 months, the effect of SRP waned and the following therapies produced significant results when compared to SRP; SURG+AMOX+MET, SURG+TET, SURG, and SURG+AMOX+MET+TET, which were also significantly effective when compared to TET. From the 12th months visit through to the 24th months visit, the effectiveness of all therapies leveled off (see also Fig. S1). After 12 months, SURG+AMOX+MET+TET would be a better choice than TET (*p*\<0.01), better than SRP at 18 months (*p*\<0.01), and at 24 months, it was better than SRP and TET (*p* \<0.01).

Decreases in PD of \>1.5 mm {#S20018}
---------------------------

[Table 4](#T0004){ref-type="table"} and S2 show estimates obtained from the analysis of model 2. The effectiveness of therapies including SURG in reducing PD by \>1.5 mm over time is clearly seen in [Table 4](#T0004){ref-type="table"}. SURG combined with AMOX, MET, and TET was significantly more likely to achieve PD reduction of \>1.5 mm than any other therapy. The odds of former smokers gaining on PD more than 1.5 mm was significantly reduced by 36% and was also reduced significantly by 39% in patient who were smokers compared to patients who had never smoked before.

###### 

Odds ratios and their confidence intervals from a multilevel logistic regression model on PD reduction of more than 1.5 mm for sites that had a baseline PD of at least 5 mm

  Therapy             6 months estimate (SE)                                  12 months estimate (SE)                                18 months estimate (SE)                               24 months estimate (SE)
  ------------------- ------------------------------------------------------- ------------------------------------------------------ ----------------------------------------------------- -----------------------------------------------------
  SURG+AMOX+MET       5.47 (3.70, 8.10)[\*](#TF0004){ref-type="table-fn"}     7.77 (5.25, 11.50)[\*](#TF0004){ref-type="table-fn"}   5.93 (4.01, 8.78)[\*](#TF0004){ref-type="table-fn"}   6.30 (4.25, 9.32)[\*](#TF0004){ref-type="table-fn"}
  SURG+TET            6.36 (4.47, 9.05)[\*](#TF0004){ref-type="table-fn"}     4.95 (3.48, 7.05)[\*](#TF0004){ref-type="table-fn"}    5.53 (3.81, 8.02)[\*](#TF0004){ref-type="table-fn"}   6.23 (4.30, 9.05)[\*](#TF0004){ref-type="table-fn"}
  SURG                3.86 (2.71, 5.49)[\*](#TF0004){ref-type="table-fn"}     2.64 (1.85, 3.75)[\*](#TF0004){ref-type="table-fn"}    2.83 (1.99, 4.03)[\*](#TF0004){ref-type="table-fn"}   2.83 (1.99, 4.03)[\*](#TF0004){ref-type="table-fn"}
  AMOX+MET+TET        2.36 (1.69, 3.30)[\*](#TF0004){ref-type="table-fn"}     2.35 (1.69, 3.30)[\*](#TF0004){ref-type="table-fn"}    2.14 (1.53, 2.98)[\*](#TF0004){ref-type="table-fn"}   2.51 (1.80, 3.50)[\*](#TF0004){ref-type="table-fn"}
  AMOX+MET            1.38 (0.95, 2.00)                                       1.68 (1.16, 2.44)[\*](#TF0004){ref-type="table-fn"}    1.35 (0.93, 1.96)                                     1.54 (1.06, 2.23)[\*](#TF0004){ref-type="table-fn"}
  TET                 1.05 (0.75, 1.47)                                       1.02 (0.73, 1.42)                                      0.98 (0.70, 1.37)                                     0.98 (0.70, 1.37)
  SURG+MET+AMOX+TET   3.82 (2.63, 5.54)^[\*](#TF0004){ref-type="table-fn"}^   2.75 (1.93, 3.91)[\*](#TF0004){ref-type="table-fn"}    2.80 (1.93, 4.06)[\*](#TF0004){ref-type="table-fn"}   3.35 (2.31, 4.87)[\*](#TF0004){ref-type="table-fn"}

Sites that had been surgically treated only (SURG) were 3.86 times more likely to gain 1.5 mm of PD after 6 months and 4.95 times more likely to gain 1.5 mm of PD after 12 months compared to SRP. However, the odds ratios for antibiotics only were relatively smaller than the odds ratios for SURG and SURG plus antibiotics. For example, the odds ratios for sites treated with AMOX+MET+TET were 2.36 and 2.35 after 6 and 12 months respectively when compared to SRP. On the other hand, sites treated with SURG+AMOX+MET were 5.47 and 7.77 times more likely to gain 1.5 mm of PD after 6 and 12 months respectively when compared to SRP after 3 months. We conclude that at any point in time, these therapies were more likely to have PD reductions of more than 1.5 mm when compared to SRP at 3 months post treatment.

All therapies were compared to SRP. Other fixed effects from the model are given in Table S1.

\*Significant results at 0.05 compared to SRP.

CAL loss/gain {#S20019}
-------------

[Table 5](#T0005){ref-type="table"} presents mean changes in CAL for the effect of all treatments over time when compared to SRP obtained by fitting model 1. Negative estimates imply that there was gain of CAL and positive estimates represent further loss of CAL. SURG increased further loss of CAL compared to SRP at the 12-month visit. Sites that were surgically treated had lost more CAL than their baseline level conditions. However, when SURG was combined with AMOX+MET+TET, significant gain of CAL was observed. AMOX+MET produced significant gain of CAL from the 6-month visit.

###### 

Results from fitting a linear multilevel regression model for changes in treatment effect over time on CAL in sites that had a baseline probing depth of at least 5 mm using the restricted maximum likelihood estimation (REML)

  Therapy             3 months estimate 95% (CI)                            6 months estimate 95%(CI)                                12 months estimate (SE)                                  18 months estimate (SE)                                  24 months estimate (SE)
  ------------------- ----------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------
  SURG+AMOX+MET       0.11 (−0.12, 0.33)                                    0.04 (−0.19, 0.26)                                       −0.05 (−0.27, 0.17)                                      −0.21 (−0.43, 0.01)                                      −0.21 (−0.43, 0.01)
  SURG+TET            0.32 (0.12, 0.53)[\*](#TF0005){ref-type="table-fn"}   −0.03 (−0.24, 0.18)                                      0.03 (−0.18, 0.23)                                       −0.04 (−0.26, 0.16)                                      −0.10 (−0.30, 0.12)
  SURG                0.49 (0.29, 0.69)[\*](#TF0005){ref-type="table-fn"}   0.48 (0.28, 0.68)[\*](#TF0005){ref-type="table-fn"}      0.61 (0.40, 0.80)[\*](#TF0005){ref-type="table-fn"}      0.44 (0.25, 0.66)[\*](#TF0005){ref-type="table-fn"}      0.40 (0.20, 0.60)[\*](#TF0005){ref-type="table-fn"}
  AMOX+MET+TET        −0.01 (−0.36, 0.09)                                   −0.39 (−0.58, −0.21)[\*](#TF0005){ref-type="table-fn"}   −0.47 (−0.67, −0.28)[\*](#TF0005){ref-type="table-fn"}   −0.52 (−0.70, −0.32)[\*](#TF0005){ref-type="table-fn"}   −0.54 (−0.73, −0.34)^[\*](#TF0005){ref-type="table-fn"}^
  AMOX+MET            −0.14 (−0.36, 0.09)                                   −0.51 (−0.74, −0.30)[\*](#TF0005){ref-type="table-fn"}   −0.55 (−0.77, −0.33)[\*](#TF0005){ref-type="table-fn"}   −0.63 (−0.84, −0.40)[\*](#TF0005){ref-type="table-fn"}   −0.67 (−0.90, −0.45)[\*](#TF0005){ref-type="table-fn"}
  TET                 0.07 (−0.12, 0.27)                                    −0.05 (−0.25, 0.14)                                      0.03 (−0.18, 0.22)                                       −0.27 (−0.46, −0.08)[\*](#TF0005){ref-type="table-fn"}   −0.25 (−0.45, −0.06)[\*](#TF0005){ref-type="table-fn"}
  SURG+MET+AMOX+TET   −0.05 (−0.27, 0.16)                                   −0.27 (−0.48, −0.07)[\*](#TF0005){ref-type="table-fn"}   −0.22 (−0.43, −0.01)[\*](#TF0005){ref-type="table-fn"}   −0.27 (−0.48, −0.07)[\*](#TF0005){ref-type="table-fn"}   −0.38 (−0.60, −0.18)[\*](#TF0005){ref-type="table-fn"}

Patient sites that had been surgically treated only experienced significant CAL loss over time. These sites had a mean CAL loss of 0.49 mm after 3 months and a mean CAL loss of 0.40 mm after 24 months compared to SRP. However, significant reversal in CAL loss was observed over time when SURG was combined with MET, AMOX and TET. For example, SURG+MET+AMOX+TET had a significant mean CAL gain of 0.27 mm after 6 months, 0.22 mm after 12 months, 0.27 mm after 18 months and 0.38 mm after 24 months compared to SRP at baseline conditions. On the other hand, sites that were treated with antibiotics only also had reversals in CAL when compared to SRP over time. AMOX+MET resulted in a mean CAL gain of 0.14 mm after 3 months, 0.51 mm after 6 months, 0.55 mm after 12 months, 0.63 mm after 18 months, and 0.67 mm after 24 months compared to SRP at baseline conditions.

All therapies were compared to SRP. Other fixed effects of the model are given in [Table 3](#T0003){ref-type="table"}.

\*Significant results at 0.05 when compared to SRP at baseline visit. Negative estimates from the model results imply that there was CAL gain and positive estimates represent further CAL loss.

In Fig. S4, sites that were treated with SURG+ AMOX+MET had the least mean loss in clinical attachment. As shown in Fig. S5, only sites that had been treated with AMOX+MET+TET, AMOX+MET, and SURG+TET had slight gains in clinical attachment compared to their baseline conditions after 6 months. However, sites that were treated with AMOX+MET+TET gained most on clinical attachment but SURG treated sites gained less (Fig. S6).

Fixed effects on CAL {#S20020}
--------------------

The fixed effects on CAL from fitting model 1 are shown in [Table 3](#T0003){ref-type="table"}. All tooth site-level covariates like visible plaque, BOP, gingival redness, and suppuration produced highly significant positive estimates, thus were strong predictors for further loss of CAL. We did not find any effect of past smoking on loss of CAL but current smokers had higher risk of further loss of CAL.

However, we did not find other significant predictors, which either reduced or increased chances of sites gaining CAL by \>1.5 mm in the logistic multilevel model (results not shown).

Pairwise treatment comparison on CAL {#S20021}
------------------------------------

We also carried out Tukey\'s all-pairwise comparison of the treatments on CAL and the results given in Table S3 include only comparisons that had significant outcomes. After 3 months, sites that were treated with SURG+AMOX+MET were on average 1.39 mm deeper than sites that were treated with AMOX+MET+TET. Surgically treated sites were on average 1.31 mm deeper after 18 months and 1.26 mm deeper after 24 months compared to sites that were treated with AMOX+MET+TET.

Discussion {#S0022}
==========

A multilevel approach to study factors influencing the outcome of periodontal treatment has been used previously ([@CIT0036]--[@CIT0039]). The advantage of this approach over the traditional methods of generalized linear models is that it takes into account the relatedness of observations measured over time.

The results of the present study revealed that, for sites with a baseline PD of at least 5 mm, SURG and any therapy combined with SURG significantly reduced PD. When combined with AMOX, MET, and TET, SURG produced highly significant clinical benefits, which were maintained throughout the 2-year study period. Our results indicate that, if non-surgical therapies are to be used in arresting periodontitis, then the best therapy would be AMOX+MET+TET. These antibiotics must be used as a combination therapy since using them on their own does not produce long-lasting clinical benefits. On the other hand, if surgical treatment is preferred, then the best choice would be to combine SURG with AMOX, MET, and TET. Actually, this study revealed that SURG+AMOX+MET+TET produced more clinical benefits than any other treatment. Also Goodson et al. ([@CIT0035]) found that AMOX+MET provided CAL gain and PD reduction.

We did not find any effect of gender, race, or nationality on PD. However, site level effects such as baseline PD, accumulation of visible plaque, gingival redness, BOP, and suppuration were significant predictors of PD increase. The effect of past and present smoking was also highly significant, and each year increase in age was significantly associated with an increase in PD.

In terms of CAL loss, major improvements in the clinical parameters occurred from 6 months in subjects who were treated with AMOX+MET+TET, AMOX+MET, and SURG+AMOX+MET+TET. Sites from patients who had been surgically treated experienced an increase in CAL loss. This might be due to a detrimental effect on osteoblasts through SURG. CAL loss was common in all sites that had been surgically treated only. Although SURG increased CAL loss, the effect could be improved if SURG was combined with antibiotics. We concluded that combination therapies with SURG were better than SURG at maintaining post-treatment effects on attachment.

In the present study, we did not find the effect of race and past smoking habits on loss of attachment in treated patients although current smokers and males were at a higher risk of CAL loss. This is in concordance with previous observations that responses after periodontal treatment are modified by cigarette smoking ([@CIT0024]--[@CIT0026]). However, accumulation of visible plaque, BOP, gingival redness, and suppuration were significant predictors of further CAL loss.

Our study revealed that sites of the Swedish subjects experienced significant CAL loss after treatment compared to sites of the American subjects. In a study of 79 Swedish and 79 US citizens with a healthy periodontium or minimal periodontal disease, Haffajee et al. ([@CIT0040]) found differences in the subgingival microbiota of the two populations. After adjusting for multiple comparisons five species (*Actinomyces naeslundii* genospecies 1, *Streptococcus sanguinis*, *Eikenella corrodens*, *Tannerella forsythia*, and *Prevotella melaninogenica*) were more abundant in the Swedish than in the American patients. How the microbiota relates to clinical changes in the present study groups remains to be investigated.

Periodontal diseases are common infections in man in which the supporting tissues of teeth are attacked resulting in CAL loss. They are common even in developed countries and a leading cause of tooth loss ([@CIT0001]). Despite the fact that different periodontal therapies are being used, continued CAL loss is common in some patients. The current study aimed to investigate the maintenance over time of clinical effects after different combinations of treatments of periodontitis. The major objective was to find a treatment that could arrest periodontal breakdown and maintain the beneficial effects of treatment during a 2-year follow-up period. We have shown that while standard periodontal treatments such as SRP or SURG may improve periodontal conditions, the use of adjunctive systemic or local antibiotic treatments would be a better choice especially if used as combination therapies. If SURG is to be used, it should be combined with AMOX+MET+TET to maintain the best clinical results.

The present study is part of a series of studies in modeling of infectious disease using periodontitis as basis where we try to combine concepts and techniques from different disciplines. The use of multilevel analysis is on the frontier in periodontal research. However, available software for analyzing such models sometimes gives different results, and if the data are huge and depending on the hierarchy of the model to be fitted, they tend to converge slowly and in some cases never converge at all.
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